Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 1/20 | 0.39 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.39 |
| ▸ | PLAU | P00749 | 2/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.36 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3400737 | 0.72 | PTGDR2 (0.41) | ALDH1A1HDAC3HDAC1HDAC2 | |
| Trifluoroacetic Acid SCHEMBL21925539 | 0.69 | LTA4H (0.49) | PLAUALDH1A1 | |
| SCHEMBL2747511 | 0.68 | ALDH1A1 (0.47) | CTRB1ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL2367354 | 0.67 | ALDH1A1 (0.50) | CTRB1ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL27766342 | 0.67 | ALDH1A1 (0.50) | CTRB1ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL28278079 | 0.67 | ALPI (0.54) | CTRB1ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL7550184 | 0.66 | LTA4H (0.51) | ITGB3ITGA2B | |
| Trifluoroacetic Acid SCHEMBL7550182 | 0.66 | LTA4H (0.51) | ITGB3ITGA2B | |
| Trifluoroacetic Acid SCHEMBL28101939 | 0.66 | ALDH1A1 (0.79) | ALDH1A1 | |
| Benzyl Carbamate SCHEMBL27962908 | 0.66 | ALDH1A1 (0.52) | PLAUALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2250157-B1 | NOVEL HETEROCYCLIC COMPOUNDS | PANACEA BIOTEC LTD (IN) | 2014-11-05 | — | — | EP | disclosed |
| US-8455479-B2 | Heterocyclic compounds | PANACEA BIOTEC LIMITED (IN) | 2013-06-04 | — | — | US | disclosed |
| US-20100311732-A1 | NOVEL HETEROCYCLIC COMPOUNDS | PANACEA BIOTEC PHARMA LIMITED (IN) | 2010-12-09 | — | — | US | disclosed |
| EP-2250157-A1 | NOVEL HETEROCYCLIC COMPOUNDS | Panacea Biotec Limited (IN) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009093269-A1 | NOVEL HETEROCYCLIC COMPOUNDS | PANACEA BIOTEC LIMITED (IN) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311732-A1 | NOVEL HETEROCYCLIC COMPOUNDS | DPP4, DPP3, DPP8 | ITGA4 1457/4885ITGB7 4034/4885PLAU 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.